We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > respiratory syncytial virus

News List

GSK to begin final-stage trials of respiratory syncytial virus vaccine expresspharma
October 22, 2020
GlaxoSmithKline said it would move its experimental vaccine against the respiratory syncytial virus (RSV), a cause of pneumonia in toddlers and the elderly, into the final stage of testing, encouraged by mid-stage trial results.
Antigen study provides a new approach to vaccine development for RSV europeanpharmaceuticalreview
March 14, 2018
Medical researchers point to a promising route for designing an effective vaccine for the respiratory syncytial virus…
Arsanis and Adimab Enter Into License Agreement to Target Respiratory Syncytial Virus (RSV) With Mon americanpharmaceuticalreview
February 28, 2017
Arsanis, Inc., a clinical-stage biopharmaceutical company developing targeted monoclonal antibodies for pre-emptive and post-infection treatment of serious infectious diseases,